Stock Analysis

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

Today we're going to take a look at the well-established DexCom, Inc. (NASDAQ:DXCM). The company's stock saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$90.75 and falling to the lows of US$75.26. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether DexCom's current trading price of US$81.96 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at DexCom’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for DexCom

What Is DexCom Worth?

Good news, investors! DexCom is still a bargain right now. Our valuation model shows that the intrinsic value for the stock is $113.51, but it is currently trading at US$81.96 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, DexCom’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What does the future of DexCom look like?

earnings-and-revenue-growth
NasdaqGS:DXCM Earnings and Revenue Growth March 6th 2025

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to more than double over the next couple of years, the future seems bright for DexCom. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? Since DXCM is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on DXCM for a while, now might be the time to make a leap. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy DXCM. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.

Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Case in point: We've spotted 1 warning sign for DexCom you should be aware of.

If you are no longer interested in DexCom, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

The New Payments ETF Is Live on NASDAQ:

Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.

Explore how this launch could reshape portfolios

Sponsored Content

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:DXCM

DexCom

A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

Flawless balance sheet with high growth potential.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4036.0% undervalued
32 users have followed this narrative
7 users have commented on this narrative
10 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6090.7% undervalued
28 users have followed this narrative
3 users have commented on this narrative
19 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8152.6% undervalued
48 users have followed this narrative
4 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

AG
Agricola
SRL logo
Agricola on Scully Royalty ·

A case for USD $14.81 per share based on book value. Be warned, this is a micro-cap dependent on a single mine.

Fair Value:US$14.8158.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
OXY logo
composite32 on Occidental Petroleum ·

Occidental Petroleum to Become Fairly Priced at $68.29 According to Future Projections

Fair Value:US$68.2941.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RE
AGFB logo
RecMag on Agfa-Gevaert ·

Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.

Fair Value:€5.3990.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.5% undervalued
122 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8684.9% undervalued
79 users have followed this narrative
8 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3929.6% undervalued
970 users have followed this narrative
6 users have commented on this narrative
26 users have liked this narrative